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In mammalian tissues two types of cGMP-dependent
protein kinase (cGK) have been identified. In contrast to
the dimeric cGK I, cGK II purified from pig intestine was
shown previously to behave as a monomer. However,
recombinant rat cGK II was found to have hydrody-
namic parameters indicative of a homodimer. Chemical
cross-linking studies showed that pig cGK II in intesti-
nal membranes has a dimeric structure as well. How-
ever, after purification, cGK II was found to be partly
proteolyzed into C-terminal monomeric fragments.
Phosphorylation studies in rat intestinal brush borders
revealed that the potency of cGMP analogs to stimulate
or inhibit native cGK II in vitro (i.e. 8-(4-chlorophenyl-
thio)-cGMP > cGMP > b-phenyl-1,N2-etheno-8-bromo-
cGMP > b-phenyl-1,N2-etheno-cGMP and Rp-8-(4-chloro-
phenylthio)-cGMPs > Rp-b-phenyl-1,N
2-etheno-8-bromo-
cGMPs, respectively) correlated well with their potency
to stimulate or inhibit cGK II-mediated Cl2 secretion
across intestinal epithelium but differed strikingly from
their potency to affect cGK I activity. These data show
that the N terminus of cGK II is involved in dimerization
and that endogenous cGK II displays a distinct activa-
tion/inhibition profile with respect to cGMP analogs,
which permits a pharmacological dissection between
cGK II- and cGK I-mediated physiological processes.
Cyclic GMP-dependent protein kinases (cGKs)1 play an im-
portant role in the signaling of various cGMP-linked hormones
and neurotransmitters including nitric oxide (NO), natriuretic
peptides, and guanylin (1, 2). In mammalian tissues two types
of cGK have been identified. Type I cGK, consisting of a and b
isoforms, is more generally expressed and acts as a key regu-
lator of cardiovascular homeostasis (1, 2). In contrast, type II
cGK was described originally as an intestine-specific form (3).
Molecular cloning demonstrated that cGK II is indeed a dis-
tinct gene product expressed predominantly in epithelial cells
of the intestine (4), although its mRNA was also detected in
kidney, bone, and brain (4–7). Its widespread distribution in
various areas of the brain suggests an important role of cGK II
in NO/cGMP signaling in the central nervous system (6).
In the intestine, cGMP is involved in the regulation of ion
and water transport. It inhibits the uptake of NaCl and stim-
ulates the secretion of Cl2 by activating the cystic fibrosis
trans-membrane conductance regulator, a Cl2 channel that is
mutated in CF patients (8, 9). Guanylin, a small peptide de-
rived from a larger precursor protein released luminally by
intestinal epithelial cells, may function as the physiological
activator of the cGMP-mediated signaling pathway in intestine
by activating guanylyl cyclase C (10, 11). Heat-stable entero-
toxins secreted by various pathogenic strains of Escherichia
coli mimic the action of guanylin and elicit a severe secretory
diarrhea by hyperactivating guanylyl cyclase C (8, 9). Electro-
physiological and immunolocalization studies have provided
evidence for a key role for cGK II as a mediator of the cGMP-
provoked intestinal Cl2 secretion (12–14). The critical role of
cGK II in STa/cGMP-induced diarrhea was recently confirmed
by pharmacological and gene disruption techniques (7, 15).
Sequence comparison and biochemical analysis revealed a
large degree of similarity in the structural organization of cGK
I and II (2–5). Both isotypes possess two cGMP binding do-
mains on one polypeptide chain which is covalently coupled to
a catalytic domain. Their N terminus contains an autoinhibi-
tory region, one or more autophosphorylation sites, and a
leucine zipper motif, and both proteins are devoid of hydropho-
bic trans-membrane domains. Despite these similarities, cGK
II was shown to differ from soluble dimeric type I cGK in that
it behaved as a membrane- and cytoskeleton-associated protein
in intestinal brush borders and as a monomer following its
solubilization and purification (3). However, recombinant
mouse brain cGK II was reported to be soluble and dimeric
after expression in mammalian and insect cells (5, 16). In
contrast, recombinant rat intestinal cGK II was found to be
tightly bound to the membrane after expression in similar cell
systems (4, 17, 18), but its oligomerization state was not estab-
lished. Furthermore, the Ka values for cGMP and cGMP ana-
logs of recombinant rat intestine cGK II purified from Sf9 cells
(17) differed considerably from those of recombinant mouse
brain cGK II, which contained an additional N-terminal histi-
dine tag (16).
Since rat and mouse cGK II have very similar sequences, are
endogenously both membrane-bound in intestine, and are ac-
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tivable by similar concentrations of cGMP after expression in
COS-1 cells (5, 18), the observed kinetic and structural differ-
ences among purified cGK II preparations may reflect artifacts
of the expression system and/or purification rather than fun-
damental differences. To circumvent such potential artifacts,
we characterized the oligomerization state of cGK II and its
kinetic properties in an environment most relevant for its phys-
iological functioning, i.e. intestinal brush border membranes.
We also compared the stimulatory or inhibitory potency of
various cGMP analogs toward cGK II in vitro, with their effects
on Cl2 secretion in rat intestinal epithelium, presumably a
cGK II-mediated process (7, 9, 12–15).
We report here that the endogenous intestinal membrane-
bound type II cGMP-dependent protein kinase exists as a
dimer and displays a distinct activation profile with respect to
cGMP analogs, which permits discrimination between cGK II
and cGK I effects in physiological processes.
EXPERIMENTAL PROCEDURES
Materials—Disuccinimidyl suberate was obtained from Pierce, and
3-isobutyl-1-methylxanthine was from Sigma. Polyclonal cGK II or cGK
I antibodies, raised against recombinant cGK II or cGK Ib expressed in
E. coli, were prepared as described (12). The cGK substrate peptide 2A3
(RRKVSKQE) and the Walsh inhibitor peptide (protein kinase A inhib-
itor-(5–24)-amide) were synthesized by D. Palm (University of Wu¨rz-
burg, Germany), and the cGMP analogs were from Biolog (Bremen).
cGK I (primarily the Ia isoform; Ref. 13) was purified from bovine lung
as described (19).
Preparation of Various cGK II-containing Membranes and Purified
cGK II—Confluent HEK-293 or NIH-3T3 cells, stably transfected with
cGK II (18), were washed twice with ice-cold phosphate-buffered saline,
scraped with a rubber policeman in buffer A (150 mM NaCl, 10 mM
NaPO4, pH 7.4, 1 mM EDTA, 100 mg/ml trypsin inhibitor, and 20 mg/ml
leupeptin) and processed directly or frozen in liquid N2 and stored at
280 °C. The cells were homogenized by brief sonication (three bursts of
3 s, peak-to-peak amplitude 15–20 mm), and a crude membrane fraction
was prepared by centrifugation for 15 min at 20,000 3 g. Membranes
from HEK-cGK II cells were resuspended in buffer A (2–3 mg of protein/
ml), and membranes from 3T3-cGK II cells (which had lower basal
protein kinase activity in cGMP activation assays) were resuspended to
1 mg of protein/ml in buffer B (20 mM Tris/HCl, pH 7.4, 5 mM b-mer-
captoethanol, 2 mM EDTA, 100 mg/ml trypsin inhibitor, and 20 mg/ml
leupeptin).
Non-vesiculated brush border caps were prepared from jejunum and
ileum of male Wistar rats by vibration of everted intestine in hypotonic
EDTA buffer and low speed centrifugation, essentially as described
previously (20), and were finally resuspended to 0.4 mg of protein/ml in
buffer B.
Brush border membrane vesicles were isolated from everted pig
intestine by freeze-thawing, followed by Mg21 precipitation according to
Ref. 21. cGK II was solubilized from HEK-cGK II membranes or pig
brush border membrane vesicles by addition of 0.5 M NaCl and 1%
Triton X-100 and subsequently purified by affinity chromatography on
8-(2-aminoethyl)-amino-cAMP-Sepharose as described (3).
Gel Filtration and Sucrose Density Gradient Centrifugation—Gel
filtration was performed essentially as described (22) using Superose 6
HR 10/30 or Superdex 200 HR 10/30 analytical gel filtration columns
(Pharmacia Biotech Inc.) equilibrated and subsequently eluted at 0.2
ml/min with 500 mM NaCl, 10 mM sodium phosphate buffer, pH 7.4, 10
mM EDTA, and 0.1% Triton X-100. Fractions of 400 ml were collected
and analyzed by immunoblotting or protein kinase activity assays. For
each experiment the column was calibrated using standards.
Sucrose density centrifugation was performed with linear 7.5–25%
sucrose gradients in the same buffer used for gel filtration (22). Appar-
ent sedimentation coefficients (sw, 20) were calculated by plotting the
distance from the top of the gradient against the position of the follow-
ing standards: catalase (11.3 S), bovine serum albumin (4.9 S), and
cytochrome c (1.9 S).
The molecular mass (m) of cGK I and cGK II was calculated from:
m 5 6phNasw, 20/(1 2 yr) where h 5 viscosity of medium, n 5 Avo-
gadro’s number, a 5 Stokes radius, sw, 20 5 sedimentation coefficient, y
5 partial specific volume, and r 5 density of the medium. We assumed
y for proteins to be 0.73 cm3/g (22).
Protein Sequencing and Cross-linking of cGK II—Purified pig cGK II
was separated by SDS-PAGE and blotted to polyvinylidene difluoride
ProblottR membrane. Pieces of membrane containing the 75- and 70-
kDa forms of cGK II were cut out separately, and both protein frag-
ments were N-terminally sequenced by automatic Edman degradation
with a 473A protein sequencer (Applied Biosystems).
For cross-linking, samples (2 mg of protein/ml) were incubated for 15
min at 0 °C in 10 mM phosphate buffer, pH 7.4, 100 mM NaCl, 10 mM
EDTA with or without 0.6 mM disuccinimidyl suberate. The reaction
was stopped by addition of SDS-PAGE sample buffer and cGK II was
analyzed by immunoblotting.
Immunoblotting and Protein Kinase Assays—Immunoblotting was
performed as described earlier (23). Immunoreactive proteins were
detected after incubation with cGK II or cGK I antibody (1:3000) by the
enhanced chemiluminescence method (Amersham Corp.) and quanti-
tated by densitometric scanning (Bio-Rad, model 620).
Protein kinase activity was determined by incubation of the samples
(4–10 mg of membrane protein in case of cGK II or 30 ng of purified cGK
I provided with 10 mg of bovine serum albumin) at 30 °C for different
times in 40 ml of 20 mM Tris/HCl, pH 7.4, 10 mM MgCl2, 5 mM b-mer-
captoethanol, 0.1 mM 3-isobutyl-1-methylxanthine, 25 mM sodium
b-glycerophosphate, 200 nM protein kinase A inhibitor, 0.1 mg/ml cGK
substrate peptide 2A3 (RRKVSKQE; Ref. 17), 1 mCi of [g-32P]ATP, and
various concentrations of nonradioactive Mg-ATP and cGMP or cGMP
analogs as indicated. The reaction was started by addition of 10-ml
aliquots of the cGK II preparations to 30 ml of prewarmed incubation
buffer and quenched by addition of 10 ml of 0.5 M EDTA. The samples
were subsequently centrifuged for 10 min at 20,000 3 g. The pellet
fraction was resuspended in SDS-PAGE sample buffer for determina-
tion of the autophosphorylation of cGK II (3), and 15 ml of the super-
natant was spotted in duplicate on sheets of P-81 chromatography
paper (Whatman). After 4 washes with 1% phosphoric acid the amount
of label incorporated was quantitated with the Molecular Imaging Sys-
tem GS-363 (Bio-Rad). The phosphotransferase activity of cGK II as
measured in intestinal brush border and 3T3 cell membranes and the
activity of cGK I were linear with the amount of enzyme up to the
concentration used in the kinetic study and with time up to 4 min in the
presence of relatively high ATP concentrations ($300 mM). However, in
the presence of low ATP, the cGK II kinase activity started to deviate
from linearity after 2 min. This nonlinearity was independent of the
concentration of cGMP or cGMP analogs and apparently resulted from
ATP depletion caused by the action of endogenous ATPases (data not
shown). The Km of cGK II for ATP was therefore determined from 2-min
incubations, whereas the kinetic parameters for the cGMP analogs
were routinely determined on the basis of 4-min incubations. The latter
condition resulted in similar kinetic values but higher signal to noise
ratios in comparison with 2-min incubations.
Electrical Measurements in Rat Intestinal Mucosa—A 1-cm long seg-
ment of rat cecum was removed under light diethyl ether anesthesia.
The muscle layers were stripped off by blunt dissection, and the mucosa
was mounted in an Ussing chamber (0.3-cm2 area exposed) for meas-
urements of short-circuit current (Isc) across the tissue as described
(24). Dose-response curves were obtained by cumulative additions of
agonists or antagonists, and subsequent measurements of the plateau
phase of the ISC reached 10–20 min after each addition.
Calculation of Kinetic Parameters and Determination of Lipophilicity
of cGMP Analogs—The values for EC50, IC50, and apparent Ka (defined
as the concentration required for half-maximal activation) were deter-
mined from dose-response curves fitted by the program Slidewrite. Km
and Hill coefficients were calculated with the program Enzfitter. Ki
values were determined from Dixon plots at half-maximal concentra-
tion of agonist (cGMP), assuming a single site. The lipophilicities of
cGMP analogs were determined by gradient reversed phase chromatog-
raphy essentially as described (25) and comparable to common log p
values.
RESULTS
Oligomeric State of Recombinant Rat Intestine and Endoge-
nous Pig Intestine cGK II—Immunoblots demonstrated that
recombinant rat cGK II solubilized from HEK 293 membranes
was eluted from gel filtration as a single peak with a Stokes
radius of 6.6 which is significantly larger than that of purified
cGK Ia (5.1) eluted under the same conditions (Fig. 1A and
Table I). Velocity sedimentation analysis likewise revealed sin-
gle peaks for cGK II and Ia with sedimentation coefficients of
6.8 and 7.2 S, respectively (Table I). From these hydrodynamic
parameters the molecular mass of cGK II was calculated as 190
kDa, more than twice the monomeric mass of 87 kDa (4),
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indicating that cGK II most likely exists as a homodimer in
solution. cGK II immunoprecipitation or purification by cAMP-
Sepharose chromatography did not reveal any associated pro-
teins that could falsify the mass determination (data not
shown, Ref. 18).
In previous studies cGK II purified from pig intestine was
found to behave as a monomer in gel filtration and sucrose
density sedimentation analyses, although kinase activity, not
immunoblotting as above, was used for cGK II detection (3). We
therefore compared the hydrodynamic parameters of recombi-
nant rat cGK II with those of native pig cGK II after purifica-
tion. As shown in Table I, purification had no effect on the
dimeric state of recombinant rat cGK II. However, purified pig
cGK II was recovered in two major peaks after gel filtration as
detected by immunoblotting (see Fig. 1B). In the first peak,
full-length cGK II (86 kDa) eluted at a position indicative of a
dimer. Subsequently, 75- and 70-kDa cGK II fragments eluted
at a position corresponding to a Stokes radius of 3.5 nm, similar
to that found for monomeric cGK II previously (3). In accord-
ance with the previous study, most of the kinase activity
(.90%) was recovered in the second peak (data not shown). The
proteins in the second peak were identified by protein sequenc-
ing as C-terminal, proteolytic fragments of cGK II. The N-
terminal sequences VPLDV and PPEF obtained from the 75-
and the 70-kDa form, respectively, matched those of a 75-kDa
cGK II fragment beginning at Val101 and of a 70-kDa fragment
starting at Pro139 (4).
To exclude the possibility that cGK II dimerization could be
an artifact of the solubilization process, we compared the oli-
gomeric structure of cGK II in membranes with that of solubi-
lized cGK II by chemical cross-linking. As shown in Fig. 2,
addition of the cross-linker disuccinimidyl suberate to pig
brush border membrane vesicles or to membranes of HEK cells
stably transfected with recombinant cGK II, either before or
after solubilization, resulted in the appearance of a cGK II
complex at the position of a dimer (170 kDa) in SDS-PAGE in
all cases, indicating that cGK II is also dimeric in membranes.
The additional cross-linked bands observed at 80- and 210-kDa
positions may represent intrachain or multiple interchain
cross-linked forms of cGK II.
Characterization of cGK II Activity in Rat Intestinal Brush
Border Membranes—Non-vesiculated brush border caps
freshly isolated from rat intestine were found to offer a suitable
model for measuring cGK II activity in its native membrane
environment. They are enriched in cGK II (0.5–1 mg of ki-
nase/mg of protein; Refs. 3, 21), contain no detectable levels of
cGK I (data not shown, cf. Refs. 3, 9, and 12), and are fully
accessible to ATP and exogenous peptide substrates (21). Fur-
thermore, cGMP could stimulate the phosphorylation of exog-
enous substrate by brush border preparations to a similar
extent (7-fold) as reported for purified recombinant cGK II (Fig.
3; Refs. 16 and 17). The apparent Km of membrane-bound cGK
II for the substrate peptide 2A3 was found to be similar to that
of cGK I (0.10 and 0.12 mM, respectively; data not shown).
FIG. 2. Cross-link pattern of recombinant and endogenous
cGK II. Membranes from HEK 293 cells stably expressing rat cGK II
(293-cGK II) and pig brush border membrane vesicles (BBMV) were
incubated either directly (mem) or after solubilization with 0.5 M NaCl
and 1% Triton X-100 (sol) in the presence or absence of 0.6 mM disuc-
cinimidyl suberate (DSS). After separation on 7.5% SDS-PAGE, cGK II
was detected by immunoblotting. Arrowheads indicate the positions of
the 86-kDa monomeric and 170-kDa dimeric forms of cGK II.
TABLE I
Hydrodynamic parameters of recombinant and endogenous cGK II
The Stokes radius was determined by gel filtration; the sedimenta-
tion coefficient by sucrose density centrifugation, and the molecular
weight was calculated from these parameters as described under “Ex-
perimental Procedures.” Recombinant cGK II was analyzed either di-
rectly after solubilization of membranes from HEK-293 cells stably
transfected with rat cGK II (Recomb. cGK II) or after subsequent
purification (recomb. cGK II pure). cGK II purified from pig intestine
was found to consist of a 86-kDa full-length form and two fragments of
approximately 75 and 70 kDa (see Fig. 1). Purified bovine lung cGK I
(consisting mainly of the type 1a form) was added to the recombinant
cGK II preparations as an internal standard (Stokes radius 5 5.0–5.3
nm, apparent s20,w 5 6.9–7.8 S and Mr 5 150,000–178,000; Refs. 3, 13,
and 27). Data represent means 6 S.E. of three experiments, ND, not
determined.
Sample Stokes radius Apparent s20,w
Mr 3 10
23
calculated
nm S
Recomb. cGK II (rat) 6.6 6 0.2 6.8 6 0.3 190
Recomb. cGK II pure 6.4 6 0.2 7.0 6 0.2 190
cGK II pure (pig intestine)
86-kDa form 6.3 6 0.2 ND
75–70-kDa forms 3.5 6 0.1 ND
cGK I pure (bovine lung) 5.1 6 0.2 7.2 6 0.4 157
FIG. 1. Gel filtration profiles of crude recombinant and puri-
fied endogenous cGK II. A, solubilized membrane proteins from HEK
293 cells stably expressing rat intestine cGK II were mixed with puri-
fied bovine cGK I and applied to a Superdex 200 HR gel filtration
column. After elution, the presence of cGK was monitored in each
fraction by immunoblotting using specific antibodies against cGK II and
cGK I. B, purified pig intestine cGK II was subjected to gel filtration,
and the cGK II content of the fractions eluted was determined by
immunoblotting using a specific antibody against cGK II. On the left the
molecular masses of the immunoreactive forms of cGK II are indicated
in kDa. Fraction numbers are indicated below the panels. BC denotes
the original preparation before it was injected on the column. The
elution positions of standards are indicated for ferritin (Stokes radius,
a 5 6.1 nm), catalase (a 5 5.2 nm), and bovine serum albumin (BSA)
(a 5 3.5 nm).
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However, endogenous cGK II at saturating cGMP (10 mM) has
a relatively high Km for ATP (0.40 mM) in comparison to cGK I
(0.066 mM) (see Fig. 4A). Moreover, ATP was observed to de-
crease the sensitivity of cGK II for cGMP. As shown in Fig. 4B,
the apparent Ka for cGMP shifted more than 10-fold, from 50
nM at 10 mM ATP to 560 nM at 1 mM ATP. A similar shift in the
apparent Ka for cGMP by ATP in the range of 10–100 mM was
noticed in case of cGK I. In the following experiments we
routinely determined cGK kinase activity in the presence of
300 mM ATP, since this condition ensured a relatively high
signal-to-noise ratio and was comparable with that used in
similar studies characterizing purified cGK II (16, 17). At 300
mM ATP using 2A3 as substrate, the apparent Ka for cGMP of
endogenous cGK II was found to be almost identical to that of
purified bovine lung cGK I (0.36 and 0.38 mM, respectively; Fig.
4B and Table II). Using the same conditions, a similar apparent
Ka for cGMP (0.31 6 0.03 mM; n 5 3) was found for recombinant
membrane-bound cGK II expressed in NIH 3T3 cells (not
shown), indicating that the sensitivity of recombinant rat cGK
II for cGMP is similar to that of endogenous rat cGK II and is
not critically dependent on its native environment. However,
solubilization of recombinant cGK II with Triton X-100 and 0.5
M NaCl caused a small increase (1.6 6 0.2-fold; n 5 3) in its
apparent Ka for cGMP (not shown). We determined the Ka for
cGMP in solubilized 3T3-cGK II membranes, because cGK II in
solubilized rat intestinal brush borders was found to be par-
tially converted into 75–70-kDa proteolytic fragments during
protein kinase assays (data not shown), similar to pig cGK II
during purification (Fig. 1B).
To further characterize native cGK II, we determined the
apparent Ka for various cGMP analogs. The membrane-per-
meant analog 8-pCPT-cGMP appeared 4–5 times more potent
than cGMP in activating cGK II, whereas PET-cGMP and
8-Br-PET-cGMP, in comparison with cGMP, were relatively
poor agonists, showing 12- and 5-fold higher apparent Ka val-
ues, respectively (Fig. 3 and Table II). Both cGMP and 8-pCPT-
cGMP, but not the two PET-cGMP derivatives, showed cooper-
ative kinetics, as apparent from their Hill coefficient of 1.5 6
0.2 (n 5 3 for both; not shown).
In addition to stimulating substrate phosphorylation, cGMP
was shown previously to increase the autophosphorylation of
cGK II in brush border membranes (3). To establish whether
both processes have similar kinetic characteristics, we com-
FIG. 3. Stimulation of protein kinase activity in rat intestinal
brush border caps by cGMP and cGMP analogs. Phosphorylation
of 2A3 by rat intestinal brush border caps was measured in the presence
of 300 mM ATP and various concentrations of cGMP (), 8-pCPT-cGMP
(f), 8-Br-PET-cGMP (l), or PET-cGMP (l). Data are means 6 S.E. of
three experiments.
FIG. 4. Kinetic properties of cGK II- and cGK I-catalyzed 2A3
phosphorylation. A, phosphotransferase activity of cGK II in rat
intestinal brush border caps (l) and of purified bovine lung cGK I (E)
plotted at various concentrations of ATP in the presence of 10 mM cGMP.
Data are expressed as percentage of the Vmax values, which were 5 6 1
nmol/min/mg protein and 2.7 6 0.5 mmol/min/mg protein for cGK II and
cGK I, respectively. B, the apparent Ka for cGMP of the phosphotrans-
ferase activity of cGK II in rat intestinal brush border caps (l) and of
purified bovine lung cGK I (E) measured at various concentrations of
ATP. Data are means 6 S.E. of three experiments.
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pared their ATP and cGMP analog sensitivity. Surprisingly,
under the same assay conditions the Km for ATP of cGK II
autophosphorylation was 50-fold lower (5–10 mM) than for 2A3
phosphorylation (data not shown). We therefore determined
apparent Ka values for cGMP and cGMP analogs for cGK II
autophosphorylation at low concentrations of ATP (5 mM). As
shown in Table II, there is a close correlation between the
relative potency of the cGMP analogs to stimulate auto- and
substrate phosphorylation, although 2A3 phosphorylation re-
quired 5–10-fold higher concentrations of cGMP or 8-pCPT-
cGMP than self-phosphorylation (in the presence of 2A3) when
determined at the same (low) concentration of ATP (data not
shown; cf. Table II and Fig. 4B).
Another possible difference between autophosphorylation
and substrate phosphorylation by cGK II may be their response
to Rp-diastereoisomers of phosphorothioate-modified cGMP an-
alogs. These compounds were previously shown to stimulate
autophosphorylation of cGK II in rat intestinal brush border
membranes (9) but to inhibit substrate phosphorylation by
purified recombinant cGK I and II (16, 17). To exclude the
possibility that the different responses to Rp-cGMPS analogs
were caused by differences in the origin/environment of cGK II
(purified recombinant versus membrane-bound endogenous),
we tested these analogs on cGK II activity in brush border
membranes. As shown in Fig. 5 and Table II, both Rp-8-pCPT-
cGMPS and Rp-8-Br-PET-cGMPS inhibited 2A3 phosphoryla-
tion by endogenous membrane-bound cGK II in a competitive
fashion. At a half-maximal concentration of cGMP, the Ki val-
ues for Rp-8-pCPT-cGMPS and Rp-8-Br-PET-cGMPS deter-
mined from Dixon plots were 0.15 and 0.45 mM, respectively
(Fig. 5).
To allow a direct comparison between the kinetic properties
of cGK II and cGK I, we determined the analog specificity of
purified bovine lung cGK I under the same conditions as used
for cGK II. As shown in Fig. 6, pCPT-cGMP was a more potent
stimulator of cGK II compared with cGK I, whereas the 8-Br-
PET and PET derivatives of cGMP were relatively selective
activators of cGK I. Similarly, Rp-Br-PET-cGMPS was found to
preferentially inhibit cGK I, whereas Rp-pCPT-cGMPS dis-
played an opposite selectivity. Furthermore, the Rp-cGMPS
analogs failed to completely inhibit the cGMP-stimulated ac-
tivity of cGK I (maximal inhibition 70%, data not shown) due to
agonistic effects of these partial antagonists occurring at
higher concentrations. A similar agonistic effect of Rp-pCPT-
cGMPS concentrations in the millimolar range has been re-
ported previously for both cGK I and II (17).
Effects of cGMP Analogs on Cl2 Secretion in Intestinal Epi-
thelium—To evaluate whether the analog specificity of cGK II
determined in vitro has any relevance for its activation of
physiological substrates in intact epithelial cells, we examined
the effects of membrane-permeant cGMP analogs on intestinal
Cl2 secretion as monitored by short-circuit current (ISC) meas-
urements in rat cecum in Ussing chambers. In this intestinal
segment cGK II was found to be colocalized with the cystic
FIG. 5. Inhibition of cGMP-stimulated protein kinase activity
in rat intestinal brush border caps by Rp diastereoisomers of
phosphorothio-cGMP analogs. Phosphorylation of 2A3 by rat intes-
tinal brush border caps was measured using 300 mM ATP in the pres-
ence of either 0.3 mM (open symbols) or 3 mM (closed symbols) cGMP plus
various concentrations of Rp-8-pCPT-cGMPS (E, l) or Rp-8-Br-PET-
cGMPS (, ). Data are expressed as percentage of the phosphotrans-
ferase activity in the absence of Rp-cGMPS analogs and are the
means 6 S.E. of three experiments. Inset, Dixon plot for the determi-
nation of Ki values (abscissa, concentration of Rp-cGMPS in mM; ordi-
nate, reciprocal value of enzyme activity expressed in nmol21zminzmg
protein).
TABLE II
Comparison of the potencies of cGMP analogs to stimulate or inhibit phosphorylation of 2A3 and auto-phosphorylation in rat intestinal brush
border caps with their effects on short circuit currents in rat cecum
Autophosphorylation of cGK II or phosphorylation of 2A3 was measured by incubation of brush border caps in the presence of 5 or 300 mM ATP,
respectively, and various concentrations of cGMP or the cGMP analogs indicated. IC50 values for the Rp analogs on the 2A3 phosphorylation were
determined in the additional presence of 0.3 or 3 mM cGMP. Changes in short circuit current (Isc) were measured in stripped rat cecum in an Ussing
chamber after cumulative additions of permeable cGMP analogs to the serosal side. IC50 values for the Rp analogs were determined after
stimulation with 2.5 mM 8-pCPT-cGMP (cf. Fig. 6). Kinetic parameters were derived from dose-response plots as described under “Experimental
Procedures” (cf. Figs. 3 and 5) and are means 6 S.E. of at least three experiments. ND, not determined.
cGMP analog
Phosphorylation, apparent Ka
DIsc
EC50
Lipophilicity
2A3,
300 mM ATPa
Auto,
5 mM ATPa log Kw
Relative
lipophilicity
mM mM
cGMP 0.36 6 0.09 0.005 ND 0.77 1
PET-cGMP 4.2 6 1.5 0.2 850 6 300 2.47 50
8-pCPT-cGMP 0.08 6 0.01 0.0005 4 6 1 2.52 56
8-Br-PET-cGMP 1.6 6 0.4 ND 200 6 40 2.83 115
IC50
b IC50
0.3 mM cGMPc 3 mM cGMPc 2.5 mM pCPT-cGMPc
mM mM
Rp-8-pCPT-cGMPS 0.29 6 0.06 5.4 6 0.7 14 6 4 2.6 68
Rp-8-Br-PET-cGMPS 0.9 6 0.3 13.4 6 4.1 14 6 5 2.83 115
a ATP concentrations chosen are close to the Km for ATP of each phosphorylation reaction.
b Based on 2A3 phosphorylation only.
c Concentration of agonist.
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fibrosis trans-membrane conductance regulator Cl2 channel in
the apical membrane of the crypt cells, in line with the rela-
tively large increase in Cl2 secretion provoked by the cGK-
specific agonist 8-Br-cGMP in this tissue (12). As expected from
the relatively low apparent Ka of cGK II for 8-pCPT-cGMP,
micromolar concentrations of this analog could stimulate ISC
(Fig. 7 and Table II), whereas 8-Br-PET-cGMP and PET-cGMP,
relatively poor agonists of cGK II in vitro, showed EC50 values
in the submillimolar range (Table II). The difference between
the cGMP analogs cannot be caused by a difference in mem-
brane permeability since 8-Br-PET-cGMP and PET-cGMP
have a higher or equal lipophilicity, respectively, compared
with 8-pCPT-cGMP (Table II). Furthermore, if the different
lipophilicities of the Rp cGMPS analogs were taken into ac-
count, their inhibitory effects on 8-pCPT-cGMP-stimulated ISC
(see Fig. 7) correlated well with their IC50 values found in in
vitro cGK II protein kinase assays (Table II), further corrobo-
rating the notion that the analog specificity of cGK II in intact
cells and in isolated membranes is very similar.
DISCUSSION
Type II and type I cGK isoenzymes are likely to play distinct
physiological roles, as judged from their differences in tissue
expression, subcellular localization, and functional properties
in vitro (2–5, 12–18). These different characteristics could in
principle be exploited to assess the involvement of a specific
cGK isoform in a cGMP-regulated cellular process. However
detailed analyses of the molecular properties of cGK II have so
far been primarily confined to recombinant and/or purified
enzyme preparations, and the results may not be representa-
tive for cGK II in its native membrane environment, e.g. due to
possible differences in posttranslational modifications, loss of
modulatory components, proteolysis or protein oxidation. In-
deed pronounced differences in the membrane localization, oli-
gomerization status, and kinetic properties of various prepara-
tions of cGK II have been reported (3–5, 16–18). These
apparent discrepancies urged us to re-evaluate some of the
structural and functional properties of cGK II in its native
environment, the apical membrane of intestinal epithelial cells.
Pig cGK II was characterized as a dimer in brush border
membranes, as was soluble mouse cGK II expressed in Sf9 cells
(16). The monomeric behavior of purified pig cGK II described
previously (3) appeared to result from the presence of catalyt-
ically active C-terminal 75- and 70-kDa proteolytic fragments
in this preparation, most likely generated during purification
by a specific endogenous protease characterized previously in
intestinal brush borders (26). The observation that these pro-
teolytic forms are monomeric indicates that dimerization of
cGK II is critically dependent on a structural domain located
within the first 100 amino acids. This is consistent with a
dimerization role for the leucine zipper motif recognized in this
region of cGK II (4). The leucine-isoleucine repeat is conserved
in all cGK sequences examined (4) and has been shown to
dimerize an N-terminal fragment of cGK Ia in vitro (27). Both
the detergent-solubilized recombinant and endogenous cGK II
observed in the present study were found to have significantly
larger Stokes radii and the recombinant cGK II a smaller
sedimentation coefficient as compared with either cGK I (Table
I; 3, 16, 28) or the soluble recombinant mouse cGK II described
by Gamm et al. (16). This suggests that the molecular shape of
solubilized particulate cGK II is more elongated than that of
cGK I and very different from the almost spherical form of
soluble mouse cGK II. However, the primary amino acid se-
quences of rat intestinal and mouse brain cGK II (4, 5, correc-
tion in Ref. 16) are nearly identical, suggesting that the higher
degree structures of these proteins should be quite similar.
Perhaps their shapes may be influenced by different N-termi-
nal modifications, since rat intestinal cGK II appears to be
myristoylated (18), whereas recombinant mouse brain cGK II
was modified with an N-terminal histidine tag (16). Certainly
these differences may be one explanation for the membrane
localization of endogenous pig and rat intestinal cGK II (3, 12),
as well as rat intestinal cGK II expressed in HEK 293, Sf9, and
COS cells (4, 17, 18), whereas mouse brain cGK II expressed in
COS and Sf9 cells remained soluble (5, 16).
FIG. 6. Comparison of the specificity of cGK I and cGK II for
cGMP analogs. Apparent Ka values were determined from dose-re-
sponse curves of 2A3 phosphorylation by cGK II in rat intestinal brush
border caps (open bars) and purified bovine lung cGK I (hatched bars) in
the presence of 300 mM ATP and various concentrations of cGMP or the
cGMP analogs indicated (cf. Fig. 3 and Table II). Apparent Ki values for
the Rp analogs of cGMPS were determined at a half-maximally stimu-
lating concentration of cGMP (0.3 mM) from Dixon plots (cf. Fig. 5), after
correction for a basal stimulatory effect of Rp analogs in the absence of
cGMP in case of cGK I. Data are expressed relative to the apparent Ka
for cGMP in each experiment and are means 6 S.E. of three
experiments.
FIG. 7. Inhibition of 8-pCPT-cGMP-stimulated short-circuit
current in rat cecum by RP-8-pCPT-cGMPS. Short-circuit current
(ISC) was measured in stripped rat cecum in an Ussing chamber. At the
time points indicated with an arrow a single dose of 8-pCPT-cGMP (2.5
mM) was added to the serosal site, followed by sequential serosal addi-
tions of Rp-8-pCPT-cGMPS (mM concentrations shown) resulting in final
cumulative concentrations of 5, 10, 20, and 40 mM.
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Another discrepancy between the various preparations of
cGK II is their sensitivity to cGMP and cGMP analogs. Part of
these differences might be explained by variations in assay
conditions, in particular the ATP concentration, which could
shift the apparent Ka of cGK II for cGMP by as much as 10-fold
(Fig. 4). A similar modulatory effect of ATP was observed for
cGK I (Fig. 4B), in line with previous reports describing down-
ward shifts in binding affinity of cGK I and cAMP-dependent
protein kinase type I for cGMP and cAMP, at concentrations of
ATP around the Km (29–31). This suggests a similar mode of
interaction between the ATP-bound catalytic domain and the
regulatory domain of all three cyclic nucleotide-dependent pro-
tein kinases, resulting in an apparent competition between
ATP and cyclic nucleotides (31). However, the effect of ATP on
cGMP affinity in kinase activity measurements was particu-
larly prominent in case of cGK II which displayed an unusually
high Km for ATP (400 mM) in comparison to cAMP-dependent
protein kinase (5 mM; Ref. 31) and cGK I (66 mM, this study;
20–50 mM; Refs. 29 and 30).
After correction for the different ATP concentrations em-
ployed in each assay (using the data plotted in Fig. 4B), the
apparent Ka for cGMP of endogenous rat cGK II was found to be
approximately 3-fold higher than that of recombinant rat cGK
II purified from Sf9 cells (17), however, 3-fold lower than that
of either recombinant rat cGK II solubilized from COS-1 cells
(18) or histidine-tagged recombinant mouse cGK II purified
from Sf9 cells (16), and similar to the apparent Ka for recom-
binant mouse cGK II expressed in COS cells (5). The lack of
consistent or major differences between native cGK II and the
various preparations of cGK II obtained after solubilization or
purification, suggests that the characteristics of cGK II are not
dramatically influenced by the membrane environment. Indeed
when tested directly, solubilization of rat cGK II expressed in
3T3 fibroblasts resulted only in a slight (1.6-fold) increase in its
apparent Ka for cGMP.
A reasonable but not perfect correspondence was also found
between the effects of cGMP analogs on endogenous cGK II and
the purified recombinant enzymes described previously. For
instance PET-cGMP had a low affinity for both endogenous rat
cGK II (4.2 mM; Table II) and for recombinant mouse cGK II
purified from Sf9 cells (4.7 mM; Ref. 16). In contrast, PET-cGMP
had the same high affinity (0.06 mM) as had cGMP (0.04 mM) for
the recombinant rat enzyme purified from Sf9 cells (17). How-
ever, the latter preparation, similar to endogenous rat cGK II,
was stimulated by relatively low levels of 8-pCPT-cGMP (3.5
and 80 nM, respectively; Ref. 17). Furthermore, the endogenous
rat enzyme, similar to recombinant rat and mouse cGK II
purified from Sf9 cells, was inhibitable by RP analogs of
cGMPS.
The inhibition of exogenous substrate phosphorylation by Rp
analogs clearly differs from their stimulatory effects on cGK II
autophosphorylation in brush border membranes (9). The ap-
parent Ka for cGMP was also different for substrate- and au-
tophosphorylation, the latter being 5–10-fold lower. Since the
apparent Ka of cGMP for autophosphorylation was close to the
Kd of cGMP determined previously for the high affinity site of
cGK II (3), it is tempting to suggest that autophosphorylation is
stimulated by occupancy of only one of the cyclic nucleotide
binding sites available (i.e. the “high affinity” or “slow” site),
whereas substrate phosphorylation apparently requires both
sites for optimal activity. Whether autophosphorylation has
any effect on the kinetic properties of cGK II as described for
cGK Ia and cGK Ib (32, 33) remains to be investigated. How-
ever, a substantial influence of autophosphorylation on the
kinetic parameters determined in this study is unlikely consid-
ering the poor stoichiometry of cGK II autophosphorylation
within the relatively short incubation periods used (3) and the
observed linearity of the kinase activity with time, i.e. the
absence of a lag time (see “Experimental Procedures”).
The correlation observed here between the effects of cGMP
analogs on substrate phosphorylation and on intestinal Cl2
secretion indicates that the characteristics of cGK II deter-
mined in vitro are relevant for its functioning under physiolog-
ical conditions. This implies that the cGMP analog specificity of
cGK II, which is clearly distinct from that of cGK I (according
to this and previous studies; see refs. 14, 16, 17, 34, and 35), can
fortuitously be used to discriminate between the functional
effects of each isotype both in in vitro assays and in intact cells.
A potency order 8-pCPT-cGMP .. 8-Br-PET-cGMP . PET-
cGMP would be diagnostic for cGK II, whereas the order 8-Br-
PET-cGMP $ PET-cGMP . 8-pCPT-cGMP would indicate a
role for cGK I (a or b).
Finally our observation that Rp-cGMPS analogs, with some
degree of specificity, can inhibit cGK II-controlled functions in
intact tissues, as well as cGK I action described earlier (36, 37),
indicates that these compounds are more generally applicable
as tools to demonstrate the involvement of cGK I or II in
specific physiological processes. For example, in a separate
study of the mechanism of action of heat-stable enterotoxin
(STa) in rat intestinal epithelium, Rp-8-pCPT-cGMPS ap-
peared also able to inhibit the STa-induced Cl2 secretion (15).
These results, together with recent cGK II knockout mouse
data (7), strengthen the concept that in native intestine, cGK II
plays an important role in the salt and water secretion initiated
by activation of guanylyl cyclase C by STa, or guanylin, the
putative endogenous ligand of GC-C (9–11).
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